Košík
tovar
(prázdne)
Kontakt
Účet
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
prečítať celé
Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg (R)), Brentuximab vedotin (Adcetris (R)), and ado-trastuzumab emtansine (Kadcyla (R)), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011).
Skryť popis
- Nakladateľ: Springer International Publishing AG
- Kód:
- Rok vydania: 2016
- Jazyk: Angličtina
- Väzba: Paperback
- Počet strán: 252
- Šírka balenia: 15.5 cm
- Výška balenia: 23.7 cm
- Hĺbka balenia: 1.9 cm
- Váha balenia: 428 g
Recenzie